INFLUENCE (B-ALL)
Clinical study into finding the best fludarabine dose for children with B-cell acute lymphoblastic leukemia (B-ALL) to improve the results of CAR T-cell therapy.
Recruiting
Who can participate
Children and young adults with B-ALL who are being treated with CD19 CAR T-cell therapy (tisagenlecleucel)
Age: 0–26 years
Aim
In this study, we compare two dosing strategies for fludarabine, a chemotherapy drug that can inhibit the growth of cancer cells. We look at the doses given before CAR T-cell treatment: the current standard dose and an increased dose that is adjusted based on the amount of fludarabine measured in the child’s blood. The aim of the study is to improve the presence and function of the CAR T cells.
Background
Chimeric antigen receptor (CAR) T-cell therapy is a new treatment for children and young adults with B-ALL who do not respond sufficiently to previous treatments. This treatment uses the child’s own immune system to target leukemia cells. In 80-90% of children, the leukemia completely disappears after treatment.
To achieve long-term remission, it is important for the CAR T cells to remain active in the body for a long time. At present, this is the case in about half of children. If the CAR T cells disappear from the body too quickly, the leukemia may return. We would like to improve this outcome.
Before receiving CAR T cells, children receive chemotherapy, including fludarabine, to make space in the body so that the CAR T cells can grow more effectively. Research shows that a higher amount of fludarabine in the blood is associated with longer persistence of CAR T cells and a lower chance of the leukemia returning.
At present, every child receives a standard dose of fludarabine, but children can process medicines very differently. As a result, the actual amount of fludarabine in the blood can vary greatly from one child to another, even when they receive the same dose. In this study, we are investigating whether we can make treatment more personalized and effective by adjusting the fludarabine dose based on the amount we actually measure in each child’s blood. With this approach, we aim to achieve higher, but still safe, exposure.
By better tailoring the dose to the child’s body, we hope that the CAR T cells will remain present for longer and that the chance of the leukemia returning will be lower, without causing additional side effects. The ultimate goal is to determine exactly what dose of fludarabine each child needs for safe and optimal treatment.
In order to participate in a study please refer to your/your child’s doctor.
For international patients: please feel welcome to contact our International Patients Office.
Last reviewed
July 13, 2026
Study details
- Study details
Official title
The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemiaCancer type
B-cell acute lymphoblastic leukemia (B-ALL)
Phase
3Maximum number of participants
60, of whom approximately 12 in the Netherlands
Start date
June 19, 2026
Status
Open
Local principal investigator
Dr. Caroline Lindemans
Sponsor
Princess Máxima Center for pediatric oncology
Approval
The study of this new treatment has been reviewed by an accredited medical research ethics committee. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO.
Trial registry number
EU Clinical Trials: 2025-523096-34-00
The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.